Hereditary Hemochromatosis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene |
HFE (primary), HJV, HAMP, TFR2, SLC40A1 |
| Inheritance |
Autosomal Recessive |
| Chromosome |
6p21.3 (HFE) |
| OMIM |
235200 (HFE-related) |
| Prevalence |
1 in 200-400 (C282Y homozygotes) |
Hereditary hemochromatosis (HH) is a group of autosomal recessive genetic disorders characterized by excessive iron accumulation in tissues throughout the body. The most common form is HFE-related hemochromatosis, caused by mutations in the HFE gene on chromosome 6p21.3. This condition leads to progressive iron overload in the liver, heart, pancreas, joints, and central nervous system, potentially causing severe organ damage if left untreated.
¶ Genetics and Pathophysiology
The HFE gene encodes the hereditary hemochromatosis protein, which regulates hepcidin expression—the key hormone controlling iron absorption in the intestine.1 The two most common pathogenic variants are:
- C282Y (p.Cys282Tyr): The most frequent mutation, resulting in a cysteine-to-tyrosine substitution at position 282. Homozygotes for C282Y have significantly elevated transferrin saturation and ferritin levels.
- H63D (p.His63Asp): A milder variant that may contribute to iron overload when compound heterozygous with C282Y or in combination with other genetic or environmental factors.
In hereditary hemochromatosis, the normal feedback mechanism linking body iron stores to intestinal iron absorption is disrupted. Normally, increased hepatic iron stores stimulate hepcidin production, which reduces intestinal iron absorption. In HH, this regulatory loop fails, leading to uncontrolled iron absorption from the diet.
The excess iron accumulates primarily in:
- Liver: Hepatocytes and Kupffer cells
- Heart: Cardiac myocytes
- Pancreas: Beta cells of the Islets of Langerhans
- Pituitary gland: Leading to endocrine dysfunction
- Brain: Basal ganglia, substantia nigra, and cortical regions
Iron deposition in the basal ganglia can lead to Parkinsonian features:
- Resting tremor: Typically asymmetric
- Rigidity: Cogwheel-type rigidity
- Bradykinesia: Slowed movements
- Postural instability: Balance difficulties
These symptoms may be misdiagnosed as idiopathic Parkinson's Disease, but typically lack the classic Lewy body pathology.
¶ Cognitive Impairment and Dementia
Iron accumulation in brain parenchyma is associated with:
- Executive dysfunction
- Memory impairment
- Behavioral changes
- Progressive cognitive decline resembling Alzheimer's Disease or Frontotemporal Dementia
- Cerebellar ataxia: Iron deposition in the cerebellum
- Peripheral neuropathy: Sensorimotor neuropathy
- Hypogonadotropic hypogonadism: Pituitary involvement
- Diabetes insipidus: Hypothalamic-pituitary axis dysfunction
- Transferrin saturation: >45% is suggestive (elevated)
- Serum ferritin: Elevated (>200 ng/mL in women, >300 ng/mL in men)
- Serum iron: Elevated
- Total iron-binding capacity (TIBC): Decreased
- HFE gene sequencing for C282Y, H63D, S65C variants
- Extended genetic testing for non-HFE hemochromatosis genes (HJV, HAMP, TFR2, SLC40A1)
- MRI brain: T2-weighted hypointensity in basal ganglia, substantia nigra, and cerebellum ("iron deposition pattern")
- Quantitative susceptibility mapping (QSM): Quantifies brain iron levels
- FDG-PET: May show hypometabolism in affected regions
- Phlebotomy: Weekly phlebotomy (500 mL) until ferritin <50 ng/mL, then maintenance therapy
- Iron chelation: Deferoxamine, deferasirox, or deferiprone for patients who cannot undergo phlebotomy
- Dopaminergic medications for parkinsonian symptoms
- Multidisciplinary approach involving neurology, hepatology, and endocrinology
- Physical and occupational therapy
- Regular monitoring of ferritin, transferrin saturation, and liver function
- Annual neurological assessment for early detection of movement disorders
- Cardiac MRI and echocardiography for iron overload cardiomyopathy
Some studies suggest that iron overload may accelerate Alzheimer's Disease pathogenesis through:
- Increased oxidative stress
- Amyloid-Beta aggregation enhancement
- Tau phosphorylation promotion
- Neuronal iron dysregulation
Iron accumulation in the substantia nigra is a hallmark of Parkinson's Disease. Patients with hereditary hemochromatosis may have an increased risk of parkinsonian symptoms, and MRI findings in HH can resemble those seen in PD.
Elevated iron levels have been reported in ALS patients, and dysregulated iron metabolism may contribute to motor neuron degeneration. The relationship between HH and ALS remains an active area of research.
The study of Hereditary Hemochromatosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54[1]:328-343
- Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13[4]:399-408
- Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366[4]:348-359
- Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823[9]:1434-1443
- Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358[3]:221-230
- Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease. N Engl J Med. 2004;350[23]:2383-2397
- Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142[1]:24-38
- Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093
- Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13[10]:1045-1060
- [Demarquay G, Setiey A, Morel Y, et al. Motor Neuron Disease in a patient with hereditary hemochromatosis. Neurology. 2000;54[5]:1278-1279](https://pubmed.ncbi.nlm.nih.gov/10746608/)
- van Duijn CM, Nussey R, de Jong J, et al. Iron metabolism and the risk of Parkinson's Disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2020;91[5]:524-532
- Nandar W, Connor JR. HFE gene variants impact iron metabolism in neurodegenerative diseases. Biochim Biophys Acta. 2012;1822[9]:1333-1342
- Finazzi D, Arosio P, Cazzola M. Iron overload in neurological diseases. Ann Neurol. 2014;76[2]:301-302
- Heijer T, Swieten JC. Brain iron deposition in hereditary hemochromatosis. Neurology. 2013;80[8]:704-705
- Kowdley KV, Brown KE, Ahn J, Sundaram V. ACG Clinical Guideline: Hereditary Hemochromatosis. Am J Gastroenterol. 2019;114[8]:1202-1218
- Pham K, Eder M, Baudin M, et al. Iron and Alzheimer's Disease: from pathogenesis to therapeutic implications. Front Neurosci. 2020;14:607394
- Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a disease-modifying strategy in Parkinson's Disease: an update on clinical data. CNS Drugs. 2019;33[3]:247-267
- Goodall EF, Haque MS, Morrison KE. The association of iron and ALS: a potential shared pathway? Amyotroph Lateral Scler. 2008;9[2]:81-87